Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia

Phase 3RecruitingNCT05703178

Northwestern University452 enrolled

Overview

The main goal of this clinical trial is to test benefits of completing online pain coping skills training program in women who have been diagnosed with stage I-III breast cancer, who have completed their primary cancer treatment, who are taking an AI medication, and who have arthralgia. Arthralgia is a type of joint, bone, and muscle pain that is a common side effect of AI medications. The main questions it aims to answer are: 1. Whether online pain coping skills training reduces the severity of pain and the interference it causes in women's daily lives. 2. Whether online pain coping skills training improves emotional distress, quality of life, and adherence to AI medications. 3. Whether benefits of online pain coping skills training are at least partially caused by women's increased confidence that they can manage their pain and a reduction in unhelpful thinking patterns about pain. 4. Whether online pain coping skills training improves effects of AI medications on sleep problems and symptoms of menopause like hot flashes and night sweats. Participants can complete all parts of the study at home. They will: 1. Complete four sets of questionnaires throughout the study, which will take about 9 to 10 months. 2. Attend 3 meetings in the first month of the study, all of which can be held via a video conference. 3. Use an electronic pill bottle to track their use of their AI medication. 4. Be randomized (like flipping a coin) to one of two study arms: They will either receive education about AIs and arthralgia or they will receive this education along with access to an online pain coping skills training program. Research will compare the education group to the education plus online pain coping skills training group to see if online pain coping skills training has the benefits mentioned above.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

452

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Female sex * Aged 18 years old or older * Diagnosed with Stage 0-III hormone receptor positive breast cancer * Completed primary cancer treatment (surgery, chemotherapy, and/or radiation therapy) * Postmenopausal * Currently taking AI therapy (letrozole, exemestane, or anastrozole) * Reporting musculoskeletal pain that developed or worsened since starting AI therapy * Reporting at least 15 days of pain in the past 30 days * A worst pain rating of 4 or more on an 11 point (0-10) numerical rating scale in the past week * Based on known factors affecting their prognosis, patient is likely to be able to complete the study protocol * ECOG performance status of 0-2 * English proficient * If participants are taking analgesics, they must be on a stable analgesic regimen for at least 14 days prior to enrollment and should not have planned upward dose titration of their analgesics during the study period. (Note: Patients may elect to decrease their analgesic use during the study as per discussion with their provider. Unexpected dose adjustments including dose escalations due to unforeseen clinical need is allowed. Cannabis taken for pain relief would qualify as an analgesic) * Comfortable using a tablet computer, a computer, or a smartphone to access online training Exclusion Criteria: * Evidence of metastatic disease * Other active cancer (with the exception of non-melanoma skin cancer) * Completed chemotherapy or radiation therapy less than four weeks prior to enrollment (these treatments can cause temporary exacerbation of musculoskeletal symptoms that typically resolve spontaneously) * Completed surgery less than 8 weeks prior to enrollment (because surgery can cause temporary post-surgical pain that typically resolves in this period of time); minor surgeries may be allowed more recently than 8 weeks at the discretion of the study team * Have diagnosed or suspected condition that would interfere with informed consent or completion of study activities (e.g., significant impairment in cognition or uncorrected hearing/vision)

Outcomes

Primary Outcomes

Change in Brief Pain Inventory pain severity subscale

We will calculate the mean of the four items on this subscale, as recommended by the scale's developers, to yield a score ranging from 0 to 10; higher scores indicate more severe pain. Analyses will examine group differences in change in pain severity.

Time frame: Change in BPI pain severity from baseline to 10-14 weeks post-baseline (Follow up 1)

Change in Brief Pain Inventory pain interference subscale

We will calculate the mean of the seven items on this subscale, as recommended by the scale's developers, to yield a score ranging from 0 to 10; higher scores indicate greater interference. Analyses will examine group differences in change in pain interference.

Time frame: Change in BPI pain interference from baseline to 10-14 weeks post-baseline (Follow up 1)

Secondary Outcomes

Change in Brief Pain Inventory pain severity subscale

Time frame: Change in BPI pain severity score from baseline to 22-26 weeks post-baseline (Follow up 2)

Change in Brief Pain Inventory pain severity subscale

Time frame: Change in BPI pain severity score from baseline to 34-38 weeks post-baseline (Follow up 3)

Change in Brief Pain Inventory pain interference subscale

Time frame: Change in BPI pain severity score from baseline to 22-26 weeks post-baseline (Follow up 2)

Change in Brief Pain Inventory pain interference subscale

Time frame: Change in BPI pain severity score from baseline to 34-38 weeks post-baseline (Follow up 3)

Change in Hospital Anxiety and Depression Scale

We will reverse score items as necessary, and then sum responses to the measure's 14 items to yield a total score ranging from 0 to 42; higher scores indicate greater emotional distress. Analyses will examine group differences in change in emotional distress.

Time frame: Change in HADS score from baseline to 10-14 weeks post-baseline (Follow up 1)

Change in Hospital Anxiety and Depression Scale

Time frame: Change in HADS score from baseline to 22-26 weeks post-baseline (Follow up 2)

Change in Hospital Anxiety and Depression Scale

Time frame: Change in HADS score from baseline to 34-38 weeks post-baseline (Follow up 3)

Change in Functional Assessment of Cancer Therapy-Lymphedema (FACT-B)

We will use the total score for the FACT-B, normalizing scores according to standard scoring methods to yield a score from 0-100; higher scores indicate greater Health-Related Quality of Life (HRQoL). Analyses will examine group differences in change in HRQoL.

Time frame: Change in FACT-B total score from baseline to 10-14 weeks post-baseline (Follow up 1)

Change in Functional Assessment of Cancer Therapy-Lymphedema (FACT-B)

Time frame: Change in FACT-B total score from baseline to 22-26 weeks post-baseline (Follow up 2)

Change in Functional Assessment of Cancer Therapy-Lymphedema (FACT-B)

Time frame: Change in FACT-B total score from baseline to 34-38 weeks post-baseline (Follow up 3)

Change in Medication Adherence Rating Scale

Using standard scoring instructions, we will first rescore each of the 10 items on this scale to indicate adherence (=1) or non-adherence (=0), then sum them to yield a score from 0 to 10; higher scores indicate better self-reported medication adherence. Analyses will examine group differences in change in adherence.

Time frame: Change in MARS scores from baseline to 10-14 weeks post-baseline (Follow up 1)

Change in Medication Adherence Rating Scale

Time frame: Change in MARS scores from baseline to 22-26 weeks post-baseline (Follow up 2)

Change in Medication Adherence Rating Scale

Time frame: Change in MARS scores from baseline to 34-38 weeks post-baseline (Follow up 3)

Change in Use event data from electronic pill bottle (Medication Event Monitoring System or MEMS Cap pill bottles)

We will use data from these pill bottles, gathered daily throughout the study, to compute an adherence score (percentage of days on which the prescribed dose of medication was taken) and evaluate group differences in change in adherence from baseline to each of the post-intervention assessments.

Time frame: Change in MEMS-recorded adherence from baseline to 10-14 weeks post-baseline (Follow up 1)

Probability of optimal adherence using event data from electronic pill bottle (Medication Event Monitoring System or MEMS Cap pill bottles)

We will use data from these pill bottles, gathered daily throughout the study, to compute an adherence score (percentage of days on which the prescribed dose of medication was taken) and evaluate group differences in probability of optimal adherence, using a dichotomous variable using a cutoff of \<80% to identify sub-optimal adherence (where 80% or greater adherence is optimal).

Time frame: Probability of MEMS-recorded optimal adherence from baseline to 10-14 weeks post-baseline (Follow up 3)

Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia

Overview

Conditions

Interventions

Eligibility

Locations (2)

Outcomes

Primary Outcomes

Secondary Outcomes

Central Contacts